February 11, 2013 – Holaira, Inc., formerly Innovative Pulmonary Solutions, Inc. (IPS), a developer of medical devices to treat obstructive lung diseases, today announced the completion of its Series C private equity financing, totaling $10 million.
/wp-content/uploads/2017/06/NUVAIRA.png00Amy Wolter/wp-content/uploads/2017/06/NUVAIRA.pngAmy Wolter2013-02-11 16:31:412018-04-19 07:55:11Holaira, Formerly Innovative Pulmonary Solutions, Closes $10 Million Series C Financing
Company closed $10.6 Million Series B Financing Led by Advanced Technology Ventures SEATTLE, Wash., Sept. 20, 2012 – Innovative Pulmonary Solutions, Inc. (IPS), a developer of medical devices to treat lung diseases, announced today that Dennis Wahr, M.D., has joined the company as president and chief executive officer. Dr. Wahr is a seasoned medical device executive with proven leadership successes at multiple medical device companies. Prior to joining IPS, Wahr co-founded Lutonix in July 2007 and served as its President and CEO until CR Bard acquired the company in December 2011. Preceding its acquisition, Lutonix developed a unique drug coated […]
/wp-content/uploads/2017/06/NUVAIRA.png00Amy Wolter/wp-content/uploads/2017/06/NUVAIRA.pngAmy Wolter2013-02-10 23:51:022018-04-19 07:54:09Innovative Pulmonary Solutions Names Dennis Wahr, M.D., as President and CEO and Announces Series B Financing Milestone
"Results from this phase II trial demonstrate a significant reduction in respiratory adverse events such as COPD exacerbations and hospitalizations of greater than 50 percent. I believe these results may have important implications for COPD sufferers and their overall quality of life, as well as for healthcare costs, as there is significant expense associated with exacerbations and hospitalizations."
Dirk-Jan Slebos, Ph.D., M.D.
3750 Annapolis Lane North
Minneapolis, MN 55447